Ally Financial Inc. acquired a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,000 shares of the medical instruments supplier’s stock, valued at approximately $976,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton Dickinson and in the 1st quarter valued at about $105,000. Parkside Financial Bank & Trust raised its holdings in shares of Becton Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Becton Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares in the last quarter. Harfst & Associates Inc. raised its holdings in shares of Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares in the last quarter. Finally, QCI Asset Management Inc. NY raised its holdings in shares of Becton Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after acquiring an additional 60 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on BDX shares. Raymond James Financial, Inc. raised Becton Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price target for the company from $210.00 to $180.00 in a report on Friday, June 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton Dickinson and in a research report on Tuesday, September 12th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton Dickinson and in a research report on Friday, July 21st. Wells Fargo & Company initiated coverage on Becton Dickinson and in a research report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective on the stock. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $200.93.

ILLEGAL ACTIVITY NOTICE: “Ally Financial Inc. Invests $976,000 in Becton Dickinson and Co (BDX) Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/19/ally-financial-inc-invests-976000-in-becton-dickinson-and-co-bdx-stock.html.

Becton Dickinson and Co (NYSE:BDX) opened at 207.72 on Thursday. Becton Dickinson and Co has a 52-week low of $161.29 and a 52-week high of $207.73. The company’s 50-day moving average price is $197.61 and its 200 day moving average price is $193.51. The company has a market capitalization of $47.27 billion, a price-to-earnings ratio of 60.16 and a beta of 1.05.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton Dickinson and had a negative return on equity of 6.44% and a negative net margin of 4.38%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the previous year, the firm posted $2.35 earnings per share. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, equities analysts expect that Becton Dickinson and Co will post $9.46 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were paid a dividend of $0.73 per share. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.41%. Becton Dickinson and’s payout ratio is currently 83.43%.

In related news, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 7,463 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the transaction, the executive vice president now directly owns 29,323 shares in the company, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock worth $15,242,688 over the last three months. 1.40% of the stock is currently owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related stocks with our FREE daily email newsletter.